Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
Ryan R. Walsh, MD, PhD, Florian Krismer, MD, Wendy R. Galpern, MD, PhD, Gregor K. Wenning, MD, PhD, Phillip A. Low, MD, Glenda Halliday, PhD, Walter J. Koroshetz, MD, … Show All … , Janice Holton, MD, Niall P. Quinn, PhD, Olivier Rascol, MD, PhD, Leslie M. Shaw, PhD, David Eidelberg, MD, Pam Bower, Jeffrey L. Cummings, MD, ScD, Victor Abler, DO, Judy Biedenharn, Gal Bitan, PhD, David J. Brooks, MD, DSc, FRCP, FMedSci, Patrik Brundin, MD, PhD, Hubert Fernandez, MD, Philip Fortier, PhD, Roy Freeman, MD, Thomas Gasser, MD, Art Hewitt, PhD, MSc, Günter U. Höglinger, MD, Matt J. Huentelman, MD, Poul H. Jensen, MD, Andreas Jeromin, MD, Un Jung Kang, MD, Horacio Kaufmann, MD, Lawrence Kellerman, PhD, Vikram Khurana, MD, PhD, Thomas Klockgether, MD, Woojin Scott Kim, PhD, Carol Langer, BA, MS, Peter LeWitt, MD, Eliezer Masliah, MD, Wassilios Meissner, MD, Ronald Melki, MD, Susanne Ostrowitzki, MD, Steven Piantadosi, MD, PhD, Werner Poewe, MD, David Robertson, PhD, Cyndi Roemer, EdD, Dale Schenk, Michael Schlossmacher, MD, Jeremy D. Schmahmann, MD, Klaus Seppi, MD, Lily Shih, Andrew Siderowf, MD, MSCE, Glenn T. Stebbins, PhD, Nadia Stefanova, MD, PhD, Shoji Tsuji, MD, Sharon Sutton, and Jing Zhang, MD Show FewerAuthors Info & Affiliations
Abstract
Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowledge gaps despite recent gains in basic and clinical research. In order to make further advances, concerted international collaboration is vital. In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease. Eight topic areas were defined: pathogenesis, preclinical modeling, target identification, endophenotyping, clinical measures, imaging biomarkers, nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an expert served as a working group chair and each working group developed priority-ranked research recommendations with associated timelines and pathways to reach the intended goals. In this report, each groups' recommendations are provided.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372:249–263.
2.
Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 2010;25:341–348.
3.
Winter Y, Bezdolnyy Y, Katunina E, et al. Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010;25:349–356.
4.
Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 2013;84:136–140.
5.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284–1288.
6.
Chio A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998;13:400–405.
7.
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771–1775.
8.
Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000;355:495–496.
9.
Wermuth L, Joensen P, Bunger N, Jeune B. High prevalence of Parkinson's disease in the Faroe Islands. Neurology 1997;49:426–432.
10.
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384–393.
11.
Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835–845.
12.
Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12:264–274.
13.
Lin DJ, Hermann KL, Schmahmann JD. The diagnosis and natural history of multiple system atrophy, cerebellar type. Cerebellum 2016;15:663–679.
14.
Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: a prospective cohort study. Neurology 2015;85:1554–1561.
15.
Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 2015;14:710–719.
16.
Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132:156–171.
17.
Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008;23:294–296.
18.
Ahmed Z, Asi YT, Sailer A, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012;38:4–24.
19.
Norcliffe-Kaufmann L, Palma JA, Krismer F. Multiple system atrophy: the case for an international collaborative effort. Clin Auton Res 2015;25:81–83.
20.
Montine TJ, Koroshetz WJ, Babcock D, et al. Recommendations of the Alzheimer's disease-related dementias conference. Neurology 2014;83:851–860.
21.
Stefanova N, Wenning GK. Animal models of multiple system atrophy. Clin Auton Res 2015;25:9–17.
22.
O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131:1362–1372.
23.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–676.
24.
Krismer F, Seppi K, Tison F, et al. The Unified Multiple System Atrophy Rating Scale: intrarater reliability. Mov Disord 2012;27:1683–1685.
25.
Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19:1391–1402.
26.
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41–47.
27.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
28.
Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol 2013;260:228–236.
29.
Brooks DJ, Seppi K, Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949–964.
30.
Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis 2015;80:29–41.
Information & Authors
Information
Published In
Copyright
Copyright © 2017 American Academy of Neurology.
Publication History
Received: April 24, 2017
Accepted: September 29, 2017
Published online: December 13, 2017
Published in print: January 9, 2018
Permissions
Request permissions for this article.
Disclosure
R.R. Walsh, F. Krismer, and W.R. Galpern report no disclosures relevant to the manuscript. G.K. Wenning: consulting and advisory board membership with honoraria from Astra Zeneca and Teva Pharmaceuticals. Grants and research: Austrian Science Fund, MSA Coalition. P.A. Low reports no disclosures relevant to the manuscript. G. Halliday is National Health and Medical Research Council Senior Principal Research Fellow (1079679). W.J. Koroshetz, J. Holton, N.P. Quinn, and O. Rascol report no disclosures relevant to the manuscript. L.M. Shaw receives support from the NIH/NIA, U19 AG024904, MJ Fox Foundation for Parkinson's Disease Research, Eli Lilly, and Roche; has provided quality control oversight for the Fujirebio AlzBio3 immunoassay; and provides quality control oversight for the Roche Elecsys CSF immunoassay platform for AD biomarkers as part of his responsibilities in the ADNI study. Dr. Shaw also provides consultation to Eli Lilly, Roche, and Novartis. D. Eidelberg and P. Bower report no disclosures relevant to the manuscript. J.L. Cummings acknowledges COBRE 1P20GM109025-01A1 and Keep Memory Alive. V. Abler is an employee of Teva Pharmaceuticals. J. Biedenharn, G. Bitan, and D.J. Brooks report no disclosures relevant to the manuscript. P. Brundin has received commercial support as a consultant from Renovo Neural, Inc., Roche, Teva Inc., Lundbeck A/S, AbbVie Inc., Neuroderm, Versant Ventures/Apollo, IOS Press Partners, and Cellular Dynamics Inc. H. Fernandez, P. Fortier, R. Freeman, T. Gasser, and A. Hewitt report no disclosures relevant to the manuscript. G.U. Höglinger has served on the advisory boards for AbbVie, Alzprotect, Asceneuron, Bristol-Myers Squibb, Novartis, Roche, Sellas Life Sciences Group, and UCB; has received honoraria for scientific presentations from AbbVie, Roche, Teva, and UCB; has received research support from CurePSP, the German Academic Exchange Service (DAAD), German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), and the Sellas Life Sciences Group; and has received institutional support from the German Center for Neurodegenerative Diseases (DZNE). M.J. Huentelman: M.J.H. acknowledges R21NS093222 from the NIH, National Institutes of Neurological Disorders and Stroke. P.H. Jensen, A. Jeromin, U.J. Kang, H. Kaufmann, L. Kellerman, and V. Khurana report no disclosures relevant to the manuscript. T. Klockgether receives/has received research support from the Deutsche Forschungsgemeinschaft (DFG), the Bundesministerium für Bildung und Forschung (BMBF), the Bundesministerium für Gesundheit (BMG), the Robert Bosch Foundation, and the European Union (EU). He serves on the editorial board of The Cerebellum and the Journal of Neurology. He has received consulting fees from Biohaven, ICON Clinical Research, and Atheneum. W.S. Kim, C. Langer, P. LeWitt, E. Masliah, W. Meissner, and R. Melki report no disclosures relevant to the manuscript. S. Ostrowitzki is an employee of Genentech Inc., a Member of the Roche Group. S. Piantadosi reports no disclosures relevant to the manuscript. W. Poewe reports personal fees from AbbVie, Allergan, AstraZeneca, Boehringer-Ingelheim, Boston Scientific, Britannia, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novartis, Orion Pharma, Teva, UCB, and Zambon (consultancy and lecture fees in relation to clinical drug development programs for PD). Royalties: Thieme, Wiley Blackwell, Oxford University Press, and Cambridge University Press. D. Robertson, C. Roemer, D. Schenk, M. Schlossmacher, J.D. Schmahmann, K. Seppi, L. Shih, and A. Siderowf report no disclosures relevant to the manuscript. G.T. Stebbins: consulting and advisory board membership with honoraria: Acadia Pharmaceuticals, Adamas Pharmaceuticals, Inc., Ceregene, Inc., CHDI Management, Inc., Ingenix Pharmaceutical Services (i3 Research), Neurocrine Biosciences, Inc., Pfizer, Inc., Ultragenyx Pharmaceutical. Grants and research: NIH, Michael J. Fox Foundation for Parkinson's Research, Dystonia Coalition, CHDI, International Parkinson and Movement Disorder Society, CBD Solutions. Honoraria: International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson's Research, Food and Drug Administration. Intellectual property rights: none. Ownership interests: none. Royalties: none. Expert testimony: none. Salary: Rush University Medical Center. N. Stefanova received research grants from the Austrian Science Fund (FWF), the MSA Coalition, AstraZeneca, and BioArctic Neuroscience AB. S. Tsuji, S. Sutton, and J. Zhang report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Study Funding
Study Funded by Fight MSA.
Authors
Affiliations & Disclosures
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
AAN, travel support and speaking honoraria
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH-NIGMS, P20GM109025, Project PI, 2015-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Keep Memory Alive Foundation 2) Elaine P. Wynn & Family Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel grants from the International Parkinson's Disease and Movement Disorder Society (non-profit entity), and the Austrian Parkinson's Disease Society (non- profit entity), Ipsen Pharma (commercial) and Fight MSA (non-profit entity)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Research grant support from MSA Coalition
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
I currently am a full time employee of Janssen Research and Development/Johnson and Johnson (2015-present). During the time of this project I was an employee of NIH.
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Gregor K. Wenning, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Astra-Zeneca Speaker Honoraria (2) Lundbeck Speaker Honoraria
Editorial Boards:
1.
Clinical Autonomic Research
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Astra Zeneca
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Austrian Science Foundation, FWF SFB F4414, 2015-2019
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Phillip A. Low, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Clinical Editor for Autonomic Neuroscience
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant for WR Medical, Stillwater, MN
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH - NS44233, U54 NS065736, R01 FD004789, CTSA UL1TR000135, R01 NS092625 FDA
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Glenda Halliday, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) AAN for speaking at annual meeting (2) MDS for speaking at annual meeting (3) MSA coalition for speaking at symposium (4) Cold Spring Harbor Laboratory for participating in DLB symposium (5) AAIC for chairing their scientific program committee (6) International Soc for Frontotemporal Dementia for speaking at their international symposia (7) Aarhus University for attending the scientific review of DANDRITE (8) Lund University for speaking and collaborating with Deniz Kirik and Asa Petersen (9) Peking Union Medical College for speaking at the Chinese Brain Banking symposium (10) Novartis for speaking at their Japanese Parkinson's disease symposia (11) International Soc for Neurochemistry for participating in the scientific program committee and their international conference
Editorial Boards:
1.
Member, Editorial Board, Neurobiology and Applied Neurology (2013-) Member, Editorial Board, Translational Neurodegeneration (2011-) Member, Editorial Board, Journal of Parkinson?s Disease (2010-) Member, Editorial Board, Journal of Neural Transmission (2006-) Member, Editorial Board, Acta Neuropathologica (2005-)
Patents:
1.
NONE
Publishing Royalties:
1.
(1) Paxinos G, Halliday G, Watson C, Koutcherov Y, Wang HQ (2006) Atlas of the developing mouse brain E17.5 P0 P6. Amsterdam:Elsevier. (2) Halliday G, Barker R, Rowe D (eds.) (2011) Non-dopamine lesions in Parkinson?s disease. New York:Oxford University Press. (3) Book chapters In Paxinos G (ed.)(1990): The human nervous system. San Diego: Academic Press (4) Book chapter In Paxinos G (ed.)(1995): The rat nervous system. 2nd. Ed. Sydney: Academic Press (5) Book chapter In Paxinos G, Mai JK (eds.)(2005): The human nervous system. 2nd Ed. San Diego: Academic Press (6) Book chapter In Paxinos G (ed.)(2004): The rat nervous system. 3rd. Ed. Sydney: Academic Press
Employment, Commercial Entity:
1.
University of Sydney, Professor of Neuroscience, 2016-
Consultancies:
1.
(1) NHMRC
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) CI on NHMRC grants #1037746 (2013-2017), #1079679 (2015-2019) & 1095127(2015-2020), #1103757 (2016-2019)
Research Support, Academic Entities:
1.
(1) CI on grants from University of NSW (Goldstar 2015, infrastructure 2008- 2017 & equipment 2014, 2015, 2016, 2017) and Sydney (2017)
Research Support, Foundations and Societies:
1.
(1) CI on grants from the Michael J Fox Foundation & Shake-it-up Australia (2011-2017)
Stock/stock Options/board of Directors Compensation:
1.
(1) Chochlear (2004-present) (2) NIB Holdings (2007-present)
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
(1) Chochlear (2004-present).
Legal Proceedings:
1.
NONE
Walter J. Koroshetz, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
I am employee of National Institutes of Health
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Janice Holton, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1. Merck-Serono. Agreement to cover travel expenses to give a seminar in Geneva 8.4.2011.
Editorial Boards:
1.
Member of the editorial board Neuropathology Applied Neurobiology 2007- present Executive Editor Neuropathology Applied Neurobiology 2012- 2014 Editor-in-Chief Neuropathology Applied Neurobiology 2014 - present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
University College London, full time employment.
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
1.Alzheimer?s Research Trust. January 2008 ? December 2010 2.The Margaret Watson Memorial Trust Grant from The Sarah Matheson Trust. January 2008 ? December 2008 3. Action Medical Research November 2007 ? October 2009 4. Brain Net Europe: Support for the Queen Square Brain Bank for Neurological Disorders July 2007 ? June 2009 5.The Sarah Matheson Trust. January 2009 ? December 2011 6. Myositis Support Group June 2009 ? May 2010 and July 2015 - June 2016 7. The Multiple System Atrophy Trust. August 2012 ? July 2014 and June 2015 - January 2017 8. Michael J Fox Foundation for Parkinson?s Research December 2010 ? November 2011 July 2014-2015 9. Alzheimer?s Research UK March 2012 - February 2013 10. MSA Coalition July 2015 - June 2016 11. King Baudouin Foundation Sophia Fund May 2016-April 2018 12. Medical Research Council 2013-present 13. CBD Solutions 2014-present
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Niall P. Quinn, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1)Commercial entity, type of payment. Lecture Honorarium Teva/Lundbeck March 2015 (2)Non-profit entity, type of payment. Webinar honorarium Klinik f?r Neurologie KantonsspitalCH-9007 St.Gallen Switzerland November 2015
Editorial Boards:
1.
(1)Journal of Parkinson's Dsease Editorial Board (2010-) (2)Journal of Movement Disorders (S.Korea)International Editorial Board(2008-) (3)Movement Disorders Clinical Practice Editorial Board,(2014-15) (4)Parkinsonism and Related Disorders Editorial Board,(2015-)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Olivier Rascol, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
AbbVie Britannia Lundbeck Merck MundiPharma Sanofi Servier Teva UCB XenoPort Zambon
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Boehringer Ingelheim MundiPharma
Editorial Boards:
1.
Movement Disorders
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
AbbVie Britannia Lundbeck Merck MundiPharma Sanofi Servier Teva UCB XenoPort Zambon
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Boehringer Ingelheim Lundbeck Teva UCB
Research Support, Government Entities:
1.
Agence Nationale de la Recherche CHU de Toulouse France-Parkinson INSERM-DHOS Recherche Clinique Translationnelle MJFox Foundation
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
France Parkinson (CoPark), MJ Fox Foundation (Simvastatine)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Leslie M. Shaw, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Eli Lilly Roche Diagnostics
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Roche Diagnostics, 2016-Mexico City, speaker, expenses Eli Lilly, 2013-Indianapolis, speaker on CSF AD biomarkers Roche Diagnotics Adv Board, honorarium
Editorial Boards:
1.
Therapeutic Drug Monitoring, Editorial Board member
Patents:
1.
NONE
Publishing Royalties:
1.
The Clinical Toxicology Laboratory, Contemporary Practice of poisoning Evaluation, 2nd edition, American Association for Clinical Chemistry Press, 2013.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Roche Diagnostics; Novartis; Eli Lilly
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NIA, U19 AG024904, ADNI Biomarker Core PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
MJFox Foundation for Parkinson's Disease Research
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David Eidelberg, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) The Michael J. Fox Foundation for Parkinson's Research (2) Dystonia Medical Research Foundation Directions Committee
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Nuclear Medicine, editorial board, 1999- present (2) Current Opinion in Neurology, editorial board, 2001-present, Co-Editor-in-Chief, 07/2017-present (3) Annals of Neurology, editorial board, 2006-present (4) Journal of Neuroscience, Associate Editor, 2011-present (5) Bioelectronic Medicine, editorial board, 2014-present (6) Journal of Parkinson's Disease, editorial board, 2012- present
Patents:
1.
Coinventor of United States Patent NO. 5,632,276 (filed January 27, 1995, granted May 27, 1997) and NO. 5,873,823 (filed September 4, 1996, granted February 23, 1999), without financial gain.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
The Feinstein Institute for Medical Research, Northwell Health, not-for-profit
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH/NINDS, P50 NS071675, PI, 09/30/10?08/31/16 (2) NIH/NIAID, P01 AI073693, Co-PI, 07/03/14? 06/30/19 (3) NIH/NINDS, R01 NS072514, PI, 04/01/11?03/31/17 (4) NIH/NINDS, U10 NS077308, Site PI, 09/01/13?08/31/18 (5) NIH, R01 NS083490, Co-Investigator, 08/01/13?07/31/17 (6) NIH, U01 NS083173, Co-Investigator, 07/01/13?06/30/17 (7) NIH, R01 DC007658, Site PI, 04/01/06?03/31/17
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) The Michael J. Fox Foundation for Parkinson's Research (2) Cure Dystonia Now Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pam Bower
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
The Multiple System Atrophy Coalition (non-profit) provided reimbursement of travel expenses to attend Alpha-Synuclein Congress(Innsbruck 2015), International MSA Congress (Salerno, 2016) and Movement Disorder Society Congresses(San Diego 2015,Berlin 2016, Vancouver 2017).
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
CGI, Senior Consultant (Information Technology)- 2003 to present
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jeffrey L. Cummings, MD, ScD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Astellas, AstraZeneca, Avanir, Axovant, BiOasis Technologies, Biogen, Boehinger-Ingelheim, Bracket, Dart, Eisai, Genentech, Grifols, Intracellular Therapies, Kyowa, Lilly, Lundbeck, Medavante, Merck, Neurotrope, Novartis, Nutricia, Orion, Otsuka, Pfizer, Probiodrug, QR Pharma, Resverlogix, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Eisai, Pfizer, Lilly, Servier, Otsuka, Lundbeck, Axovant, Nutricia
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Copyright payments for use of the Neuropsychiatric Inventory
Employment, Commercial Entity:
1.
Cleveland Clinic
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Teva pharmaceuticals; drug for study Avid pharmaceuticals; tau ligand
Research Support, Government Entities:
1.
NIH COBRE grant P20GM109025
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Keep Memory Alive
Stock/stock Options/board of Directors Compensation:
1.
Dr. Cummings owns stock in ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, Neurokos, and QR pharma
License Fee Payments, Technology or Inventions:
1.
Payment for use of the Neuropsychiatric Inventory
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Expert witness/legal consultation Dr. Cummings has provided expert witness consultation regarding olanzapine and ropinerol.
Victor Abler, DO
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Teva Pharmaceutical employee Global Medical Director, 12 years
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
I receive stock options from Teva Pharmaceuticals
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Judy Biedenharn
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
MSA Coalition -board volunteer and patient advocate
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Gal Bitan, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
University of California, San Diego
Editorial Boards:
1.
Journal of Biological Chemistry, editorial board member Scientific Reports, editorial board member
Patents:
1.
1. US 8481484 B2, EP 2493859 A1 - Inhibitors of protein aggregation. 2. US 8,791,092, EP2403859 A2 - Inhibitors of protein aggregation. 3. Application No. 14/536,176 - Inhibitors of protein aggregation.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH/NIA, R01AG050721, PI, 2015-2020 2) NIH/NIA R01AG054000, PI, 2017-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Michael J. Fox Foundation 10220 2) Cure Alzheimer?s Fund 20152631 3) CurePSP Foundation 600-6-15 4) Team Parkinson/Parkinson Alliance 5) American Parkinson Disease Association 6) MSA Coalition 20170367
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David J. Brooks, MD, DSc, FRCP, FMedSci
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Member of Alzheimer UK Biomedical Science Advisory Board Member of Alzheimer Research UK Grant Advisory Board Chairman NUHS Scientific Advisory Board Singapore Chairman European Research Council Neuroscience Panel
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Honoraria from GlaxoSmithKline, Genzyme, TEVA, Merck, GE Healthcare for attending SABs.
Editorial Boards:
1.
Associate Editor of Brain and NPJ Parkinson's disease. Editorial board member of Annals of Neurology, Synapse, Basal Ganglia, J Parkinson's Disease, Parkinsonism and related disorders, Clin Neurol and Neurosur, Neurotherapeutics, Molecular Imaging and Biology Imaging Section)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
GE Healthcare, Plexxikon, GenePod, Biogen
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
GE Healthcare
Research Support, Government Entities:
1.
Danish Council for Independent Research Medical Research Council UK
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Lundbeck Foundation
Stock/stock Options/board of Directors Compensation:
1.
GE Healthcare
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
GE Healthcare
Stock/stock Options, Medical Equipment & Materials:
1.
GE Healthcare
Legal Proceedings:
1.
NONE
Patrik Brundin, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Cure Parkinson's Trust Oxford Parkinson's Disease Center World Parkinson's Coalition American Academy of Neurology Sergey Brin Family Foundation
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Pfizer Inc, travel reimbursement
Editorial Boards:
1.
Journal of Parkinson's Disease, Co-editor in Chief, 2010 to present NPJ Parkinson's Disease, Editorial Board, 2017
Patents:
1.
Teva/ H. Lundbeck A/S - Co-Inventor of Azilect (Rasagiline) in the use of treatment of olfactory deficits in PD or other conditions.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Abbvie Apollo Biologics LP NeuroDerm Renovo Neural, Inc. H. Lundbeck A/S Cellular Dynamics International, Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
R21NS093993, NIH/NINDS 12253 Michael J Fox Foundation R01NS096241, NIH via Northwestern University Cure Parkinson's Trust 30-40321-1, Michael J Fox Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
Acousort AB, Lund, 2010 to present ParkCell AB, 2009 to present Axial Biotherapeutics, 2017 to present
Legal Proceedings:
1.
NONE
Hubert Fernandez, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Dr. Fernandez is in the Steering Committee/Advisory Board of Solvay Duodopa Global Study and EMD Serono Safinamide Global Study, and the Coordinating Investigator for the Xeomin Registry, but has not received any personal compensation for these activities.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Dr. Fernandez has received honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape (as a speaker in CME events), Biogen GE Healthcare, Lundbeck, Merz, Pfizer (as a consultant).
Editorial Boards:
1.
Dr. Fernandez has received a stipend from Movement Disorders Society for serving as Medical Editor of the MDS Web Site.
Patents:
1.
Dr. Fernandez is a patent co-owner of COMPRESS, a neurosurgical candidate selection tool.
Publishing Royalties:
1.
Dr. Fernandez has received royalty payments from Demos Publishing, Manson Publishing, Springer Publishing for serving as a book author.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Dr. Fernandez has received research support from: AbbVie, Acadia, Auspex/Teva, Biotie Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, Parkinson Study Group, Rhythm, Synosia, Abbott, but has no owner interest in any pharmaceutical company. Contractual Services: AbbVie, Merz Pharmaceuticals, Auspex/Teva, Xeomin Registry Study, Ipsen Pharmaceuticals.
Research Support, Government Entities:
1.
Dr. Fernandez has received research support from NIH/NINDS
Research Support, Academic Entities:
1.
Dr. Fernandez has received research support from Huntington Study Group, Movement Disorders Society, Parkinson Study Group
Research Support, Foundations and Societies:
1.
Dr. Fernandez has received research support from Michael J. Fox Foundation, Movement Disorders Society, National Parkinson Foundation, Society of Progressive Supranuclear Palsy.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
Dr. Fernandez received Royalties: Demos Publishing.
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Philip Fortier, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Roy Freeman, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Abide, Acetylon, Astellas, Biogen, Daiichi-Sankyo, Dong, Grace, Grunental, Insys, Lundbeck, Nestle, Novartis, Pfizer, Vertex and Spinifex
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Autonomic Neuroscience - Basic and Clinical, Editor (2007-2016) Autonomic Neuroscience - Basic and Clinical, Editor-in-Chief (2016-) Clinical Autonomic Research, Editorial Board (1999-present) Clinical Journal of Pain, Assoc. Editor, 2009-2012 Clinical Journal of Pain, Editorial Board (2009-present)
Patents:
1.
NONE
Publishing Royalties:
1.
Royalties from UptoDate
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Impeto (2) Nestle (3) Pfizer
Research Support, Government Entities:
1.
(1) NIH (NHBLI), R01HL111465-01A1, PI 08/27/13-06/30/17 (2) NIH (NINDS), U54 NS 065736, Co-PI, 09/30/15-06/30/2020
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Multiple system atrophy consortium
Stock/stock Options/board of Directors Compensation:
1.
(1) Spinifex
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas Gasser, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) Joint Programming in Neurodegenerative Diseases (JPND) (2) Affiris AG
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) MedUpdate: speakers honoraria and funding for travel (2) Movement Disorders Society: funding for travel (3) Michael J Fox Foundation: funding for travel (4) UCB Pharma, (5) Novartis, (6) Merck-Serono, (7) Schwarz Pharma, (8) Boehringer Ingelheim
Editorial Boards:
1.
Parkinsonism and Related Disorders, editorial board member, since 2007
Patents:
1.
(1) KASPP (LRRK2) Gene, its Production and Use for the Detection and Treatment of Neurodegenerative Diseases
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) BMBF, JPND, 01ED1406, coordinator, 3 (2) BMBF, e:Med, 031 A 430 A, coordinator, 3 (3) BMBF, 01EK1606D, PI, 3 (4) EU, 602646, coordinator, 5
Research Support, Academic Entities:
1.
(1) DZNE, Helmholtz Association, PI, 2009 ff
Research Support, Foundations and Societies:
1.
(1) Michael J Fox Foundation (2) German Research Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Art Hewitt, PhD, MSc
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
I am an employee of Lundbeck LLC and participated in this project while receiving a salary
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
As an employee of Lundbeck LLC my travel was paid for by the company
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
I am an employee of Lundbeck LLC a company
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
I am an employee of Lundbeck LLC
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Günter U. Höglinger, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) Asceneuron, (2) Abbvie, (3) Bristol-Myers Squibb, (4) Roche, (5) UCB, (6) Novartis, (7) Sanofi, (8) Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Abbvie, (2) Roche, (3) UCB, (4) Movement Disorders Society
Editorial Boards:
1.
NONE
Patents:
1.
(1) Method for the treatment of neurodegenerative diseases. PCT/EP2015/068734.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Sellas Life Sciences Group
Research Support, Government Entities:
1.
(1) Bayerische Forschunsallianz, (2) German Ministry of Education and Research (BMBF), (3) German Academic Exchange Service (DAAD), (4) German Research Foundation (DFG), (5) German Center for Neurodegenerative Diseases (DZNE)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) CurePSP, (2) International Parkinson Foundation, (3) NOMIS Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Matt J. Huentelman, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH-NINDS R01 NS059873 Role: Principal Investigator Years: 2008-2012
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Poul H. Jensen, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
non profit entity: Michael J Fox Foundation
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
non-profit entity: Michael J Fox Foundation - Payment for attending a conference
Editorial Boards:
1.
Journal of Neuropathology and Applied Neurobiology, Editorial advisory board member 2015-2017
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Non-profit entity: Michael J Fox Foundation
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
H. Lundbeck A/S
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Michael J Fox Foundation Lundbeck Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andreas Jeromin, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Founder and CSO, Atlantic Biomarkers, LLC Scientific and Medical Advsior, Quanterix, Inc.
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Quanterix, Inc.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Banyan Biomarkers, Inc. (past) Quanterix. Corp.
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Un Jung Kang, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) American Parkinson Disease Association
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Vesicular Monoamine Transporter Gene Therapy in Parkinson?s Disease, (US Patent #6,506,378) issued by the U.S. Patent and Trademark Office on 01/14/2003 Genetically Engineered Cells that Produce L-DOPA, (US Patent #6,103,226) issued by the U.S. Patent and Trademark Office on 08/15/2000
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
medical advisory board of CVS/caremark
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH/NINDS R01 NS101982 PI 05/01/17 ? 2/28/21 (2) NIH R03 PI 05/15/16 - 03/31/18 (3) DoD/CDMRP Discovery Award PI 06/01/17 - 11/30/18 (4) NIH U01 investigator 10/1/16 - 09/30/21
Research Support, Academic Entities:
1.
Parkinson Study Group Huntington Study Group
Research Support, Foundations and Societies:
1.
(1) Parkinson's Foundation PI 07/01/2013 to 06/30/2019; (2) MJFF investigator 12/01/15 - 11/30/17
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Horacio Kaufmann, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Astra Zeneca, Lundbeck
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor in Chief Clinical Autonomic Research
Patents:
1.
NONE
Publishing Royalties:
1.
Up to Date (yearly royalties for 3 chapters) Epocrates (yearly royalties for 1 chapter)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH: Grant#: U54NS065736, U01NS078025, R01HL103988. FDA: Grant#: FDR3731-01
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Dysautonomia Foundation, Inc
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Lawrence Kellerman, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Vikram Khurana, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Co-Founder, equity holding and adviser in Yumanity Theraepeutics (myself and spouse)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
(1) Yeast to human stem cell discovery platform for neurodegenerative proteinopathies (2) Transposenet: Cross-species tool for mapping molecular networks
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Yumanity Therapeutics
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Brigham and Women's Hospital
Research Support, Foundations and Societies:
1.
Multiple System Atrophy Coalition National Ataxia Foundation Harvard Neurodiscovery Center
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
As above (see patent applications)
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas Klockgether, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1)Biohaven (2)ICON Clinical Research (3)Atheneum
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
EU Joint Programme Neurodegenerative Disease Research (JPND) ?Biomarkers for Alzhei-mer?s disease and Parkinson?s disease (BIOMARKAPD), 2012 ? 2015 EU FP7 ?Integrated European Project on Omics Research of Rare Neuromuscular and Neu-rodegenerative Diseases (Neuromics), 2012 - 2017 Patienten ohne Diagnose: Aufbau einer Interdisziplin?ren Kompetenzeinheit zur Erkennung Seltener chronischer Erkrankungen, Robert Bosch-Stiftung, 2014 ? 2016 BMBF ?Effects of acetyl-DL-leucine on cerebellar ataxia - a multicenter, randomized, double-blind, placebo- controlled, 2-way crossover phase III trial (ALCAT), Bonn site?, 2015 ? 2018 BMBF ?IDSEM-Verbundprojekt. Integrative Datensemantik f?r Neurodegenerative Forschung, Teilprojekt C?, 2016 ? 2019 EU Joint Programme Neurodegenerative Disease Research (JPND) ?European Spinocerebellar Ataxia Type 3/Machado- Joseph Disease Initiative (ESMI)?, 2016 ? 2019 EU Joint Programme Neurodegenerative Disease Research (JPND) ?Biomarkers for Alzhei-mer?s disease and Parkinson?s disease (BIOMARKAPD), 2012 ? 2014 EU FP7 ?Integrated European Project on Omics Research of Rare Neuromuscular and Neu-rodegenerative Diseases (Neuromics) Patienten ohne Diagnose: Aufbau einer Interdisziplin?ren Kompetenzeinheit zur Erkennung Seltener chronischer Erkrankungen, Robert Bosch-Stiftung, 2013 ? 2015. JPND/BMBF: European SCA3/MJD Inititiative (ESMI), 2016 - 2019 BMBF: Integrated Data Semantics, 2016 - 2019
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Woojin Scott Kim, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Carol Langer, BA, MS
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Peter LeWitt, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) Commercial entity: Acorda, Biogen Idec, Britannia, Cynapsus, Insightec, Intec, Kyowa Hakko, Lundbeck, Luye, NeuroDerm, Osmotica, Pfizer, ProStrakan, Prothena, SynAgile, Teva, Titan, USWorldMeds
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Non-profit entity: International Parkinson's and Movement Disorders Society,Society; Commercial entity: Lundbeck honorarium for talks; USWorldMeds: honorarium for talks; Acadia: honorarium for talks
Editorial Boards:
1.
1) CLINICAL NEUROPHARMACOLOGY, Editor-in-Chief, 2003- present (compensated); 2) JOURNAL OF NEURAL TRANSMISSION, editorial board, 2009- present (not compensated); 3) JOURNAL OF PARKINSON'S DISEASE, editorial board (not compensated) board, 2009-present; 4) TRANSLATIONAL NEURODEGENERATION, editorial board, 2006-present;
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Employed physician, Sensior staff physician, Henry Ford Health System, 2007-present
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Commercial entity: Acorda; commercial entity: Adamas; commercial entity: Biotie; commercial entity: Intec; commercial entity: NeuroDerm; commercial entity Pharma 2B; commercial entity: USWorldMeds;
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Academic entity: Parkinson Study Group
Research Support, Foundations and Societies:
1.
Michael J. Fox Foundation for Parkinson's Research; KiMe Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Eliezer Masliah, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
EVER Pharma and NPT sponsored travel to international scientific meeting
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Neotope Biosciences, NPT, Neurophage
Research Support, Government Entities:
1.
NIH NIA AG5131, AG18440, MH062962, AG043384
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Wassilios Meissner, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Zambon France and Astra Zeneca
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaking fees from UCB, Aguettant and MDS
Editorial Boards:
1.
Journal of Neural Transmission, field editor neurology and translational studies Journal of Parkinson's Disease
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Sanofi
Speakers' Bureaus:
1.
Speaking fees from UCB, Aguettant and MDS
Other Activities:
1.
Feed for editorial activities with Springer Nature
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
French Health Ministry, the European Community, ANR, LABEX Excellence Initiative
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Michael J Fox Foundation, France Parkinson, PSP-France and MSA Coalition.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ronald Melki, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Experimental and Molecular Medicine - Nature publishing, member of the editorial board, since 2016 (2) Neuropathology and applied neurology, Wiley, member of the editorial board since 2014
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Susanne Ostrowitzki, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Full-time employee and stock owner, Genentech Inc., A Member of the Roche Group.
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Steven Piantadosi, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1R01 CA188480-01A1 Tighiouart (PI) 09/17/14-08/31/19 NIH/NCI Design of Cancer Phase I/II Clinical Trials Using Drug Combinations of Cytotoxic and Biologic Agents The goal of this research is to develop novel Bayesian adaptive designs for early phase cancer clinical trials of drug combinations with cytotoxic and biologic agents. These trials will identify safe and efficacious dose combinations for use in large phase III trials. Role: Co-Investigator W81XWH-12-1-0447 Lyerly (PI) 09/30/12-09/29/17 DOD/Duke UniversityCedars-Sinai Medical Center Detecting and Elimination of Oncogenic Signaling networks in Pre-Malignant and Malignant Cells with Magnetic-Resonance Imaging Role: Biostatistics PI BC132150P1 Lyerly (PI) 09/30/14 ? 09/29/19 DOD/Duke University A Molecular Framework for Understanding DCIS. The over-all goal is to distinguish aggressive breast cancer from indolent cancers; overcome the problems of over diagnosis and over treatment and identify who some, not all, women get breast cancer. Role: Subaward PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Consultant with expert report; Covington & Burling LLP, wash DC
Werner Poewe, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Werner Poewe has received consultancy and lecture fees in relation to clinical drug programs for PD from AbbVie, AstraZeneca, BIAL, Biogen, Cynapsus, Britannia, Gr?nenthal, Intec, Ipsen, Lundbeck, Merz Pharmaceuticals, Novartis, Neuroderm, Orion Pharma, Prexton, Teva, UCB, and Zambon.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Werner Poewe has received consultancy and lecture fees in relation to clinical drug programs for PD from AbbVie, AstraZeneca, BIAL, Biogen, Cynapsus, Britannia, Gr?nenthal, Intec, Ipsen, Lundbeck, Merz Pharmaceuticals, Novartis, Neuroderm, Orion Pharma, Prexton, Teva, UCB, and Zambon
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
1. Therapeutics of Parkinson's Disease and Other Movement Disorders, Hallett M, Poewe W, Wiley, 2008 2. Non-motor symptoms of Parkinson's Disease, Chaudhuri R, Poewe W, Oxford University Press, 2009 3. Parkinson-Syndrome und andere Bewegungsst?rungen Hrsg. Oertel W, Deuschl G, Poewe W, Thieme 2011 4. Cambridge University Press
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Werner Poewe has received consultancy and lecture fees from Abbott, Astra Zeneca, Teva, Novartis, GSK, Boehringer-Ingelheim, UCB, Orion Pharma, Abbott and Merck Serono in relation to clinical drug development programmes for PD.
Speakers' Bureaus:
1.
Werner Poewe has received consultancy and lecture fees in relation to clinical drug programs for PD from AbbVie, AstraZeneca, BIAL, Biogen, Cynapsus, Britannia, Gr?nenthal, Intec, Ipsen, Lundbeck, Merz Pharmaceuticals, Novartis, Neuroderm, Orion Pharma, Prexton, Teva, UCB, and Zambon.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Michael J. Fox Foundation 1. ?Validation of Dyskinesia Rating Scales?, Goetz C, 2009 2.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David Robertson, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS: 2 U54 NS065736-07 PI for 7 years; NIH: P01 HL056693-19 Project Leader
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Cyndi Roemer, EdD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Dale Schenk
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Michael Schlossmacher, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
Not for profit: Parkinson Society Canada
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Non-profit: Movement Disorder Society 2017; International Synuclein Conference Athens 2017;
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Academic institute: 100%
Consultancies:
1.
For profit: Genzyme-Sanofi (USA; Canada) 2015-2017
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Government of Canada: 1) Canada Research Chair Program (PI: 2011-2016); 2)Canadian Institutes of Health Research (PI: 2010-ongoing); 3) Department of Medicine at The Ottawa Hospital.
Research Support, Academic Entities:
1.
University of Ottawa Brain and Mind Research Institute and Parkinson Research Consortium Ottawa(2013-ongoing).
Research Support, Foundations and Societies:
1.
Michael J Fox Foundation for Parkinson's Research (PI: 2013-ongoing);
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
Patent: Co-inventor for the Treatment of Synucleinopathies. IP resides with Brigham and Women's Hospital, Boston, MA.
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jeremy D. Schmahmann, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
(1) Ataxion / Cadent (2) Pfizer (3) Biogen (4) Biohaven (4) Takeda
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
The Cerebellum, Editorial Board,1999 - Cerebellum and Ataxias
Patents:
1.
NONE
Publishing Royalties:
1.
1. Schmahmann JD. (Editor). The Cerebellum and Cognition. International Review of Neurobiology. Volume 47. San Diego, Academic Press. 1997. 2. Schmahmann JD, Doyon J, Toga A, Petrides M, Evans A. MRI Atlas of the Human Cerebellum. San Diego, Academic Press. 2000. http://www.ebooks.com/ebooks/book_display.asp?IID=428486 3. Schmahmann JD, Pandya DN. Fiber Pathways of the Brain. New York, Oxford University Press. 2006. http://www.ebooks.com/ebooks/book_display.asp?IID=431410 4. Boltshauser E, Schmahmann JD. (Editors). Cerebellar Disorders in Children. Clinics in Developmental Medicine No. 191 ? 192. London, MacKeith Press. 2012. 5. Manto M, Gruol D, Schmahmann JD, Koibuchi N, Rossi F. (Editors). Handbook of the Cerebellum and Cerebellar Disorders. New York, Springer. 2012.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Ataxion / Cadent; Pfizer; Biogen; Biohaven; Takeda
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Department of Defense, 2016-7, PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) National Ataxia Foundation, 2016, PI (2) Ataxia Telangiectasia Children's Project 2016-7, PI
Stock/stock Options/board of Directors Compensation:
1.
Ataxion / Cadent
License Fee Payments, Technology or Inventions:
1.
(1) Brief Ataxia Rating Scale. The General Hospital Corporation (2) Cerebellar Cognitive Affective / Schmahmann syndrome Scale. The General Hospital Corporation
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
(1) Hyundai, expert witness, 2016
Klaus Seppi, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
received speaker honoraria from: AOP Orphan Pharmaceuticals AG (2015-2017), Abbvie (2015-2017), UCB (2015), TEVA (2016)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
consultancy fees (Commercial entities): from AbbVie (2017) and Roche (2016)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Funding from EU (EU FP7/2007-2013 Health-F4-2013-602999; 2014-2017; CO-PI), from EU (HORIZON 2020 EC project Grant 633190-FAIR-PARK-II; 2015-; CO-PI)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Funding (for Research projects) from the Michael J Fox Foundation (Project: PPMI; 2010-; CO-PI); the International Parkinson and Movement Disorder Society (Project: Validation of diagnostic criteria; 2015-; PI) and ParkinsonFonds ?sterreich (Project: visual abmormalities in PD; PI)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Lily Shih
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andrew Siderowf, MD, MSCE
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
I was a full-time employee of Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Co until May 2017
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Glenn T. Stebbins, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
1. Ultragenyx Pharmaceutical
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1. International Parkinson and Movement Disorder Society - Travel 2. Dystonia Coalition - Travel 3. American Academy of Neurology - Honoraria 4. Michael J. Fox Foundation for Parkinson's Research - Honoraria 5. Food and Drug Administration - Honoraria 6. National Institutes of Health - Honoraria 7. TOXINS - Travel 8. American Society for Experimental Neurotherapeutics - Travel
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Acadia Pharmaceuticals 2. Adamas Pharmaceuticals, Inc. 3. Ceregene, Inc. 4. CHDI Management, Inc. 5. Ingenix Pharmaceutical Services (i3 Research) 6. Neurocrine Biosciences, Inc. 7. Pfizer, Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. National Institute of Mental Health, Co-I, 2012-2015
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. Michael J. Fox Foundation for Parkinson's Research 2. CHDI 3. Dystonia Coalition 4. International Parkinson and Movement Disorder Society 5. CBD Solution
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nadia Stefanova, MD, PhD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Austrian Science Fund
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Shoji Tsuji, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial entity, speaker honoraria Dainippon Sumitomo Pharma Co. Ltd. Sanofi Novartis Mitsubishi Tanabe Pharma Co.
Editorial Boards:
1.
Neurology and Clinical Neuroscience Role: Editor-in-Chief
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI (22129001, 22129002 and 26253054)]), and the Japan Agency for Medical Research and Development (Grant-in-Aid [H26-Nanchiseishikkan Jitsuyoka-Ippan-080, 26310101, and Ninchisho Kenkyu 26340101]).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sharon Sutton
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jing Zhang, MD
From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurological Disease Neurochemical Res J of Alzheimer's disease Proteomics Insides
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Notes
Correspondence Dr. Walsh [email protected]
*
These authors contributed equally to this work.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Author Contributions
Ryan R. Walsh: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, acquisition of data, study supervision, and obtaining funding. Florian Krismer: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and acquisition of data. Wendy R. Galpern: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Gregor K. Wenning: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, and study supervision. Phillip A. Low: study concept or design, accepts responsibility for conduct of research and final approval, and contribution of vital reagents/tools/patients. Glenda M. Halliday: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, and acquisition of data. Walter J. Koroshetz: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and study supervision. Janice L. Holton: drafting/revising the manuscript, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Niall Quinn: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Olivier Rascol: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Leslie M. Shaw: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, and participated in discussions of underlying issues for studying MSA. David Eidelberg: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Pam Bower: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Jeffrey L. Cummings: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, obtaining funding, and sponsoring meeting on which manuscript is based. Victor Abler: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, acquisition of data, and study supervision. Judy Biedenharn: study concept or design and accepts responsibility for conduct of research and final approval. Gal Bitan: drafting/revising the manuscript, study concept or design, and accepts responsibility for conduct of research and final approval. David James Brooks: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and acquisition of data. Patrik Brundin: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Hubert H. Fernandez: study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, statistical analysis, and study supervision. Philip Fortier: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and acquisition of data. Roy Freeman: drafting/revising the manuscript, study concept or design, and accepts responsibility for conduct of research and final approval. Thomas Gasser: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Art Hewitt: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, acquisition of data, and obtaining funding. Gunter U. Hoglinger: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Matthew Huentelman: study concept or design and accepts responsibility for conduct of research and final approval. Poul H. Jensen: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Andreas Jeromin: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Un Jung Kang: drafting/revising the manuscript and study concept or design, accepts responsibility for conduct of research and final approval. Horacio Kaufmann: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Lawrence Kellerman: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and acquisition of data. Vikram Khurana: analysis or interpretation of data and accepts responsibility for conduct of research and final approval. Thomas Klockgether: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, and contribution to consensus process. Woojin S. Kim: drafting/revising the manuscript, study concept or design, and accepts responsibility for conduct of research and final approval. Carol Langer: study concept or design and accepts responsibility for conduct of research and final approval. Peter A. LeWitt: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, and acquisition of data. Eliezer Masliah: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Wassilios Meissner: drafting/revising the manuscript, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Ronald Melki: study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, and study supervision. Susanne Ostrowitzki: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, active participation in the MSA meeting that occurred in Las Vegas in October 2014. Steven Piantadosi: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval. Werner Poewe: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. David Robertson: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval, study supervision. Cyndi Roemer: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Dale Schenk: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Michael Schlossmacher: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and participation in a summit to review current state of the field and future needs. Jeremy D. Schmahmann: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Klaus Seppi: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, and study supervision. Lily Shih: study concept or design, accepts responsibility for conduct of research and final approval, and study supervision. Andrew D. Siderowf: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, and participated in consensus meeting to develop content. Glenn Stebbins: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Nadia Stefanova: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and accepts responsibility for conduct of research and final approval. Shoji Tsuji: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval. Sharon Sutton: study concept or design and accepts responsibility for conduct of research and final approval, MSA former board member. Jing Zhang: drafting/revising the manuscript and accepts responsibility for conduct of research and final approval.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Olivera Tamaš,
- Milija Mijajlović,
- Tamara Švabić,
- Milutin Kostić,
- Gorica Marić,
- Andona Milovanović,
- Marta Jeremić,
- Nataša Dragašević-Mišković,
- Matthew K. Bagg,
- Amelia J. Hicks,
- Sarah C. Hellewell,
- Jennie L. Ponsford,
- Natasha A. Lannin,
- Terence J. O'Brien,
- Peter A. Cameron,
- D. Jamie Cooper,
- Nick Rushworth,
- Belinda J. Gabbe,
- Melinda Fitzgerald,
- Mohamed Hamid,
- Sara Slimani,
- Houda Alloussi,
- Ahmad Bourazza,
- Deepmala Nandanwar,
- Daniel D. Truong,
- Pratheeba Jeyananthan,
- Perera U․L․K․K․,
- Jayawardhana H․M․C․S․B․,
- Deepmala Nandanwar,
- Mara D. Seier,
- Daniel D. Truong,
- Sabrina Katzdobler,
- Georg Nübling,
- Martin Klietz,
- Urban M. Fietzek,
- Carla Palleis,
- Alexander M. Bernhardt,
- Florian Wegner,
- Meret Huber,
- Sophia Rogozinski,
- Luisa-Sophie Schneider,
- Eike Jakob Spruth,
- Aline Beyle,
- Ina R. Vogt,
- Moritz Brandt,
- Niels Hansen,
- Wenzel Glanz,
- Kathrin Brockmann,
- Annika Spottke,
- Daniel C. Hoffmann,
- Oliver Peters,
- Josef Priller,
- Jens Wiltfang,
- Emrah Düzel,
- Anja Schneider,
- Björn Falkenburger,
- Thomas Klockgether,
- Thomas Gasser,
- Brigitte Nuscher,
- Christian Haass,
- Günter Höglinger,
- Johannes Levin,
- Thi Thuong Doan,
- Thuy Dung Pham,
- Duy Duan Nguyen,
- Dac Hong An Ngo,
- Trong Binh Le,
- Thanh Thao Nguyen,
- Florian Krismer,
- Patrice Péran,
- Vincent Beliveau,
- Klaus Seppi,
- Germain Arribarat,
- Anne Pavy‐Le Traon,
- Wassilios G. Meissner,
- Alexandra Foubert‐Samier,
- Margherita Fabbri,
- Michael M. Schocke,
- Mark Forrest Gordon,
- Gregor K. Wenning,
- Werner Poewe,
- Olivier Rascol,
- Christoph Scherfler,
- Roderick P.P.W.M. Maas,
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.
View options
PDF and All Supplements
Download PDF and Supplementary MaterialDownload is in progress